Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02154490 · ClinicalTrials.gov registry record
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
A clinical trial, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- 1,864
- Enrollment target
NCT02154490 is a clinical trial that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 1,864 participants.
The verdict
NCT02154490 has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- 1,864 participants
- Enrollment target
Study Summary
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a ?non-match? sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.
Interventions
- DRUG Docetaxel
- BIOLOGICAL Durvalumab
- BIOLOGICAL Ipilimumab
- DRUG Erlotinib Hydrochloride
- DRUG FGFR Inhibitor AZD4547
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,864 participants |
| Start Date | 2014-07-08 |
| Est. Completion | 2022-04-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02154490
The ClinicalTrials.gov registry entry for NCT02154490 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,864 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT02154490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02154490 about?
NCT02154490 is a clinical study titled "Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer". This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid ?Master Protocol? (S1400). The type of cancer trait (biomarker) will determ...
What is the current status of trial NCT02154490?
This trial is currently completed. The enrollment target is 1,864 participants. The study started on 2014-07-08. Estimated completion is 2022-04-15.
What interventions are being tested in trial NCT02154490?
The interventions under investigation include: Docetaxel (DRUG), Durvalumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Erlotinib Hydrochloride (DRUG), FGFR Inhibitor AZD4547 (DRUG).
Who is sponsoring clinical trial NCT02154490?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.